Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 5, 2006, Pages 1191-1196

  Ouyang, Xiaohu ^a   Piatnitski, Evgueni L ^a   Pattaropong, Vatee ^a   Chen, Xiaoling ^a   He, Hai Ying ^a   Kiselyov, Alexander S ^a   Velankar, Avdhoot ^a   Kawakami, Joel ^a   Labelle, Marc ^a   Smith II, Leon ^a   Lohman, Julia ^a   Lee, Sui Ping ^a   Malikzay, Asra ^a   Fleming, James ^a   Gerlak, Jason ^a   Wang, Ying ^a   Rosler, Robin L ^a   Zhou, Kai ^a   Mitelman, Stan ^a   Camara, Margarita ^a   Surguladze, David ^a   Doody, Jacqueline F ^a   Tuma, M Carolina ^a   more..

^a ELI LILLY AND COMPANY   (United States)

Author keywords

1,3,4 Oxadiazole; Antimitotic agent; Multiple drug resistance; Tubulin polymerization inhibitor

Indexed keywords

ANTIMITOTIC AGENT; COLCHICINE; LEAD; OXADIAZOLE DERIVATIVE; TRIAZOLE; TUBULIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING SITE; DRUG COMPETITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANIMALS; ANTIMITOTIC AGENTS; BIOPOLYMERS; CELL LINE, TUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MOLECULAR STRUCTURE; OXADIAZOLES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

ANIMALIA;

EID: 31344448309     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.11.094     Document Type: Article

References (15)

1. M.A. Jordan, and L. Wilson Nat. Rev. Cancer 4 2004 253
2. M.A. Jordan, J.A. Hadfield, N.J. Lawrence, and A.T. McGown Med. Res. Rev. 18 1998 259
3. M. Kavallaris, N.M. Verrills, and B.T. Hill Drug Resist. Update 4 2001 392
4. Q. Li, and H.L. Sham Expert Opin. Ther. Patents 12 2002 1663
5. K. Hotta, and H. Ueoka Crit. Rev. Oncol. Hematol. 55 2005 45
6. G. Bacher, B. Nickel, P. Emig, U. Vanhoefer, S. Seeber, A. Shandra, T. Klenner, and T. Beckers Cancer Res 61 2001 392
7. K. Yoshimatsu, A. Yamaguchi, H. Yoshino, and K. Kitoh Cancer Res. 57 1997 3208
8. J.A. Segreti, J.S. Polakowski, K.A. Koch, K.C. Marsh, J.L. Bauch, S.H. Rosenberg, H.L. Sham, B.F. Cox, and G.A. Reinhart Cancer Chemother. Pharmacol. 54 2004 273
9. X. Ouyang, X. Chen, E.L. Piatnitski, A.S. Kiselyov, H.-Y. He, Y. Mao, V. Pattaropong, Y. Yang, K.H. Kim, J. Kincaid, L. Smith II, W.C. Wong, S.P. Lee, D.L. Milligan, A. Malikzay, J. Fleming, J. Gerlak, D. Deevi, J.F. Doody, H.-H. Chiang, S.N. Patel, Y. Wang, R.L. Rosler, P. Kussie, M. Labelle, and M.C. Tuma Bioorg. Med. Chem. Lett. 15 2005 5154
10. S. Sunder, N.P. Peet, and R.J. Barbuch J. Heterocycl. Chem. 18 1981 1601
11. Primary alcohol and NaH were used instead of primary amine.
12. T.G.M. Dhar, C. Liu, W.J. Pitts, J. Guo, S.H. Watterson, H. Gu, C.A. Fleener, K.A. Rouleau, N.Z. Sherbina, J.C. Barrish, D.L. Hollenbaugh, and E.J. Iwanowicz Bioorg.Med. Chem. Lett. 12 2002 3125
13. S.K. Tahir, P. Kovar, S.H. Rosenberg, and S.-C. Ng BioTechniques 29 2000 156
14. Ouyang, X.; Kiselyov, A.; Chen, X.; He, H.-Y.; Kawakami, J.; Pattaropong, V.; Piatniski, E.; Tuma, M. C.; Kincaid, J. 2005, WO 2005004818.
15. Piatniski, E.; Kiselyov, A.; Hadari, Y.; Doody, J.; Ouyang, X.; Chen, X. 2004, WO 2004052280.